

Per Karsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9499012/publications.pdf>

Version: 2024-02-01

69
papers

6,528
citations

304368

22
h-index

106150

65
g-index

70
all docs

70
docs citations

70
times ranked

9115
citing authors

#	ARTICLE	IF	CITATIONS
1	Surgical outcome of graded Harada-Ito procedure in the treatment of torsional diplopia â€ a retrospective case study with long-term results. <i>Strabismus</i> , 2022, 30, 8-17.	0.4	1
2	Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up. <i>British Journal of Cancer</i> , 2022, 126, 1145-1156.	2.9	20
3	Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial. <i>European Journal of Cancer</i> , 2022, 168, 128-137.	1.3	6
4	Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial. <i>Clinical Cancer Research</i> , 2021, 27, 749-758.	3.2	10
5	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptorâ€positive Early Breast Cancer: Results from the SOLE Trial. <i>Clinical Cancer Research</i> , 2021, 27, 504-512.	3.2	5
6	Prognostic and predictive impact of stroma cells defined by PDGFRb expression in early breast cancer: results from the randomized SweBCG91RT trial. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 45-55.	1.1	8
7	Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts. <i>Cancers</i> , 2021, 13, 2209.	1.7	29
8	High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial. <i>Clinical Cancer Research</i> , 2021, 27, 3469-3477.	3.2	8
9	Genetic alterations associated with multiple primary malignancies. <i>Cancer Medicine</i> , 2021, 10, 4465-4477.	1.3	7
10	Discovery and validation of a genomic signature to identify women with early-stage invasive breast cancer who may safely omit adjuvant radiotherapy after breast-conserving surgery.. <i>Journal of Clinical Oncology</i> , 2021, 39, 512-512.	0.8	3
11	Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS). <i>Cancers</i> , 2021, 13, 6103.	1.7	21
12	Locally advanced breast cancer. <i>Breast</i> , 2021, , .	0.9	9
13	A 17-marker panel for global genomic instability in breast cancer. <i>Genomics</i> , 2020, 112, 1151-1161.	1.3	18
14	Previously diagnosed multiple primary malignancies in patients with breast carcinoma in Western Sweden between 2007 and 2018. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 221-228.	1.1	9
15	Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breastâ€conserving surgery: a longâ€term followâ€up of the SweBCG91â€RT randomised trial. <i>Molecular Oncology</i> , 2020, 14, 2713-2726.	2.1	2
16	Integrative genomics approach identifies molecular features associated with early-stage ovarian carcinoma histotypes. <i>Scientific Reports</i> , 2020, 10, 7946.	1.6	14
17	Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy. <i>Clinical Cancer Research</i> , 2020, 26, 171-182.	3.2	14
18	Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry. <i>Frontiers in Oncology</i> , 2020, 10, 162.	1.3	27

#	ARTICLE	IF	CITATIONS
19	Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens. <i>Scientific Reports</i> , 2020, 10, 5798.	1.6	106
20	No Increased Cardiac Mortality or Morbidity of Radiation Therapy in Breast Cancer Patients After Breast-Conserving Surgery: 20-Year Follow-up of the Randomized SweBCGRT Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 701-709.	0.4	19
21	Tumor-infiltrating lymphocytes in ipsilateral breast tumor recurrences predict prognosis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 546-546.	0.8	0
22	Distribution of Locoregional Breast Cancer Recurrence in Relation to Postoperative Radiation Fields and Biological Subtypes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 285-295.	0.4	15
23	Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3340-3349.	0.8	61
24	Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas. <i>BMC Cancer</i> , 2019, 19, 928.	1.1	46
25	Integration of biological factors in the treatment plan evaluation in breast cancer radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2019, 11, 54-60.	1.2	2
26	The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004â€“2014). <i>BMC Cancer</i> , 2019, 19, 187.	1.1	11
27	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. <i>British Journal of Cancer</i> , 2019, 120, 959-967.	2.9	5
28	Radiationâ€“induced genomic instability in breast carcinomas of the Swedish hemangioma cohort. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 627-635.	1.5	6
29	Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 1179-1187.	0.8	41
30	Increased Overall Mortality Even after Risk Reducing Surgery for BRCA-Positive Women in Western Sweden. <i>Genes</i> , 2019, 10, 1046.	1.0	3
31	Positive sentinel node in luminal A-like breast cancer patients - implications for adjuvant chemotherapy?. <i>Acta OncolÃ³gica</i> , 2019, 58, 162-167.	0.8	8
32	Breast cancer survival trends in different stages and age groups â€“ a population-based study 1989â€“2013. <i>Acta OncolÃ³gica</i> , 2019, 58, 45-51.	0.8	22
33	Metachronous and Synchronous Occurrence of 5 Primary Malignancies in a Female Patient between 1997 and 2013: A Case Report with Germline and Somatic Genetic Analysis. <i>Case Reports in Oncology</i> , 2018, 10, 1006-1012.	0.3	14
34	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 127-138.	5.1	91
35	Transcriptomic and genomic profiling of early-stage ovarian carcinomas associated with histotype and overall survival. <i>Oncotarget</i> , 2018, 9, 35162-35180.	0.8	10
36	Clonal relatedness in tumour pairs of breast cancer patients. <i>Breast Cancer Research</i> , 2018, 20, 96.	2.2	14

#	ARTICLE	IF	CITATIONS
37	Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 349-355.	1.1	5
38	Comprehensive transcriptomic profiling to identify breast cancer patients that may be spared adjuvant systemic therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 535-535.	0.8	1
39	Genome-wide multi-omics profiling of the 8p11-p12 amplicon in breast carcinoma. <i>Oncotarget</i> , 2018, 9, 24140-24154.	0.8	19
40	Mindfulness and its efficacy for psychological and biological responses in women with breast cancer. <i>Cancer Medicine</i> , 2017, 6, 1108-1122.	1.3	95
41	A Novel 18-Marker Panel Predicting Clinical Outcome in Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1619-1628.	1.1	1
42	Postoperative radiotherapy after DCIS: Useful for whom?. <i>Breast</i> , 2017, 34, S43-S46.	0.9	8
43	Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 3222-3229.	0.8	74
44	Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 (SBG 2004-1) randomized trial of tailored dose adjuvant chemotherapy for early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12036-e12036.	0.8	0
45	Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1601-1610.	0.8	100
46	Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VII. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 273-279.	0.4	22
47	Cyclotorsion Measured in a Patient Population Using Three Different Methods: A Comparative Study. <i>Strabismus</i> , 2016, 24, 28-36.	0.4	10
48	Purposeful Agency in Support Seeking During Cancer Treatment From a Person-Centered Perspective. <i>Global Qualitative Nursing Research</i> , 2016, 3, 233339361663067.	0.7	1
49	Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. <i>Journal of Clinical Oncology</i> , 2016, 34, 927-935.	0.8	390
50	Radiation Therapy to the Plexus Brachialis in Breast Cancer Patients: Analysis of Paresthesia in Relation to Dose and Volume. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 277-283.	0.4	16
51	Breast cancer risk and possible mechanisms of radiation-induced genomic instability in the Swedish hemangioma cohort after reanalyzed dosimetry. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2015, 775, 1-9.	0.4	33
52	Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546.	0.6	1,449
53	Effect of Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma in Situ: 20 Years Follow-Up in the Randomized SweDCIS Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 3613-3618.	0.8	184
54	Association of Nuclear-Localized Nemo-Like Kinase with Heat-Shock Protein 27 Inhibits Apoptosis in Human Breast Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e96506.	1.1	18

#	ARTICLE	IF	CITATIONS
55	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013, 24, 2206-2223.	0.6	2,805
56	Risk Factors of Developing Long-Lasting Breast Pain After Breast Cancer Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 71-78.	0.4	41
57	Timing of Radiotherapy and Outcome in Patients Receiving Adjuvant Endocrine Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 398-402.	0.4	32
58	Symptoms 10-17 years after breast cancer radiotherapy data from the randomised SWEBBCG91-RT trial. <i>Radiotherapy and Oncology</i> , 2010, 97, 281-287.	0.3	38
59	Accelerated partial breast cancer irradiation (APBI)-the future breast cancer radiotherapy?. <i>Acta Oncologica</i> , 2009, 48, 485-486.	0.8	1
60	The Role of the Number of Uninvolved Lymph Nodes in Predicting Locoregional Recurrence in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2019-2026.	0.8	67
61	SPET imaging of central muscarinic acetylcholine receptors with iodine-123 labelled E-IQNP and Z-IQNP. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 13-24.	2.2	12
62	The western Swedish BRCA1 founder mutation 3171ins5; a 3.7% conserved haplotype of today is a reminiscence of a 1500-year-old mutation. <i>European Journal of Human Genetics</i> , 2001, 9, 787-793.	1.4	50
63	A Founder Mutation of the BRCA1-Gene in Western Sweden. <i>Disease Markers</i> , 1999, 15, 99-99.	0.6	0
64	Iodine-123 labelled Z-(R,R)-IQNP: a potential radioligand for visualization of M1 and M2 muscarinic acetylcholine receptors in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 1482-1485.	3.3	10
65	Bromine-76 and carbon-11 labelled NNC 13-8199, metabolically stable benzodiazepine receptor agonists as radioligands for positron emission tomography (PET). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 1261-1267.	3.3	14
66	Effects of cocaine on [11C]norepinephrine and [11C]â²-CIT uptake in the primate peripheral organs measured by PET. <i>Annals of Nuclear Medicine</i> , 1996, 10, 85-88.	1.2	8
67	[11C]â²-CIT-FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography. , 1996, 22, 386-390.		76
68	Cancer Incidence after Radiotherapy for Skin Haemangioma During Infancy. <i>Acta Oncologica</i> , 1995, 34, 735-740.	0.8	99
69	Pet study of [11C] â²-CIT binding to monoamine transporters in the monkey and human brain. <i>Synapse</i> , 1994, 16, 93-103.	0.6	162